journal?

Journal of Serum Pharmacology and Infection Control was a monthly scientific periodical founded in 1961 in Cambridge by a consortium of researchers at the Infectious Disease Research Centre, the Institute for the History of Bacteriology, and the Pasteur Institute. It became the premier publication venue for research on serum therapy, asepsis maximalism protocols, and bacterial genetics, and remains in continuous publication.

The journal emerged from a need that had become acute by the late 1950s. The absence of reliable systemic antibacterial agents had forced medicine away from curative chemotherapy and toward prevention, containment, and passive immunization. Yet the field had no unified venue for reporting methodological work, clinical outcomes, or the theoretical foundations of infection control. Research on serum therapy appeared scattered across journals devoted to general medicine, chemistry, and veterinary medicine. The founding editors — Kenji Umezaki at Cambridge, Richard Reinhardt at the Berlin institute, and a committee from the Pasteur Institute — proposed a dedicated forum where the emerging discipline could develop and communicate.

The journal's scope encompassed several overlapping domains. Articles on serum therapy ranged from animal immunization protocols to clinical trials using the Kaplan-Meier method for survival analysis. Papers on asepsis maximalism documented hospital design, surgical technique, and the statistical outcomes of clean wards. Work in bacterial genetics — following Joshua Lederberg's foundational discoveries — examined how infection-causing traits could be inherited and selected for, a finding that explained why chemical suppression of bacteria could never be permanent. Methodological papers addressed statistical problems unique to a medicine built on prevention rather than cure.

The journal's editorial board appointed peer reviewers from the Geneva Sanitary Bureau, academic bacteriology departments, and major hospitals. Early issues averaged twelve to sixteen articles per issue, with a circulation of approximately 2,400 copies distributed to research institutions, medical schools, and hospital libraries across Western Europe, North America, and Japan. By 1975, circulation had reached 6,800, and the journal had begun publishing review articles synthesizing progress in serum therapy and infection outcomes.

Scholarly disagreement shaped the journal's pages from its inception. Papers by proponents of asepsis maximalism — arguing that contamination prevention was the sole reliable approach to infection — regularly appeared alongside work suggesting that improved serum therapy regimens might reduce the reliance on architectural and behavioral measures. The journal's editors maintained that rigorous evidence, not doctrine, should guide the field. This commitment produced some of its most consequential issues: a 1972 series on the early Halloway-Umezaki trials, a 1979 retrospective on twenty-five years of clean ward outcomes, and a 1981 collection examining bacterial genetics and the inherent limits of chemical therapy.

The journal also served as a record of the international coordination that asepsis maximalism demanded. The Bacillary Congress of Geneva published its protocols and revisions through the journal's pages, and the Geneva Sanitary Bureau used the publication to disseminate updated quarantine and laboratory standards. This dual role — scientific forum and official registry — gave it unusual authority within hospital systems and public health agencies.

By the early 21st century, Journal of Serum Pharmacology and Infection Control had become the primary archival record of how medicine reorganized itself around the absence of systemic antibacterial treatment. Its back issues constitute the most complete documentation of the transition from sulfonamide-centered chemotherapy to the serum-based approaches that emerged after 1975. Academic historians of medicine regularly cite article sequences from the 1970s and 1980s as evidence of how quickly the field adapted its theoretical foundations once it became clear that chemical cure would not arrive.

The journal changed editors twice: Kenji Umezaki served until his retirement in 1983, succeeded by a committee at Cambridge until 1995, when editorial oversight passed to an international board. Its publication frequency increased to eighteen issues per year in 1998 as research output accelerated. The journal maintains an archive of all issues since 1961 at the Infectious Disease Research Centre, the Institute for the History of Bacteriology, and the Pasteur Institute.

One recurring feature shaped the journal's intellectual character. Beginning in 1968, each issue carried a "Outcomes and Protocols" section reporting aggregate infection statistics from participating hospitals, anonymized by institution. These tables — tracking bacteraemia rates, septicaemia mortality, surgical site infection frequencies, and mean serum therapy response times — made the journal a living census of how well asepsis maximalism was performing across nations. Institutions could benchmark their own infection rates against the published averages and identify when their protocols diverged from consensus practice. This epidemiological function gave the journal an unusual status: it was simultaneously a research publication, a professional standard-setting body, and a coordinating mechanism for international medical practice.

The journal's first issue, published in February 1961, carried six articles: three on serum preparation methods from animal sera, two on clean ward design and function, and one examining statistical problems in serum therapy trials. An editorial by Kenji Umezaki stated that "the field of infection control has matured beyond the theoretical phase. We now require rigorous measurement of what works, and honest documentation of what fails." That commitment to measurement and honesty, sustained across six decades, made the journal indispensable to understanding how 20th-century medicine adapted to a world without systemic antibacterial cure.